Eli Lilly's Ozempic-rivaling weight-loss pill orforglipron could be available in early 2026. Its retatrutide may be as ...

Novo Nordisk stock jumped Friday after the Danish drugmaker announced new data for a new weight-loss drug which appeared to ...

There are several potential challengers to Novo Nordisk and Eli Lilly’s obesity drugs, and Jefferies analysts see one as ...

An analyst thinks he has cracked the code on why highflying Eli Lilly missed two quarters of Wall Street projections.

Eli Lilly hopes that a new pill it's developing can do everything ... patients taking orforglipron achieved about 14.7% weight loss, on average, almost matching Ozempic.

One of Novo Nordisk's next-generation obesity shots to follow up on the success of Wegovy helped patients lose 22% of their ...

Eli Lilly hopes that a new pill it's developing can do everything Ozempic can ... In earlier phase two trials the company sponsored, patients taking orforglipron achieved about 14.7% weight loss, on ...

Novo Nordisk announced positive trial results for its next-generation obesity drug, leading to a 7.13% surge in its share ...

Novo Nordisk's phase 1b/2a clinical trial results revealed that their investigational drug, amycretin, led to an average ...

In recent years, the pharmaceutical industry has undergone significant changes in the focus of its innovation, research and ...

Right now, the company has seven clinical trials underway exploring new molecules and ... investors to look beyond weight loss when it comes to an investment in Eli Lilly. The company is well ...